Go Pro
→ The ultimate IPO unicorn (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
$0.01
$0.01
$0.01
▼
$8.90
$451K0.13674,371 shs14,660 shs
Inotiv, Inc. stock logo
NOTV
Inotiv
$0.01
-26.0%		$0.04
$0.08
▼
$2.95
$387K3.777.42 million shs243,786 shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
-20.0%		$0.00
$0.00
▼
$0.10
$221K0.13287,139 shs55,435 shs
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
$0.03
$0.04
$0.00
▼
$14.75
$110K1.37120,908 shsN/A
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
0.00%0.00%-33.33%-67.32%-99.87%
Inotiv, Inc. stock logo
NOTV
Inotiv
0.00%0.00%-40.96%-96.22%-99.39%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00%0.00%-28.57%-28.57%-66.67%
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
$0.01
$0.01
$0.01
▼
$8.90
$451K0.13674,371 shs14,660 shs
Inotiv, Inc. stock logo
NOTV
Inotiv
$0.01
-26.0%		$0.04
$0.08
▼
$2.95
$387K3.777.42 million shs243,786 shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
-20.0%		$0.00
$0.00
▼
$0.10
$221K0.13287,139 shs55,435 shs
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
$0.03
$0.04
$0.00
▼
$14.75
$110K1.37120,908 shsN/A
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
0.00%0.00%-33.33%-67.32%-99.87%
Inotiv, Inc. stock logo
NOTV
Inotiv
0.00%0.00%-40.96%-96.22%-99.39%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00%0.00%-28.57%-28.57%-66.67%
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
1.67
Reduce$30.00299,900.00% Upside
Inotiv, Inc. stock logo
NOTV
Inotiv
2.00
Hold$1.5013,413.51% Upside
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00
N/AN/AN/A
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
N/AN/AN/AN/A($41.98) per shareN/A
Inotiv, Inc. stock logo
NOTV
Inotiv
$507.36M0.00$0.01 per share0.82$3.96 per share0.00
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$60.32M0.00N/AN/AN/A∞
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
$12.05M0.01$1.61 per share0.02($0.37) per share-0.09
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
-$8.30M-$71.01N/AN/AN/AN/AN/A-209.40%9/2/2026 (Estimated)
Inotiv, Inc. stock logo
NOTV
Inotiv
-$68.62M-$2.53N/AN/AN/A-17.14%-56.77%-8.91%N/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
-$572.84M-$0.17N/AN/AN/AN/AN/AN/A8/18/2026 (Estimated)
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
-$3.59M$3.730.01N/AN/AN/A-237.65%57.29%N/A

Latest TCON, NOTV, CERO, and SRNE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/2/2026N/A
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
-$0.7956N/AN/AN/AN/AN/A
8/18/2026N/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.42N/AN/AN/A$18.23 millionN/A
5/11/2026Q2 2026
Inotiv, Inc. stock logo
NOTV
Inotiv
-$0.6350-$0.94-$0.3050-$0.94$124.74 million$117.65 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
N/AN/AN/AN/AN/A
Inotiv, Inc. stock logo
NOTV
Inotiv
N/AN/AN/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/AN/AN/A
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
N/A
0.56
0.56
Inotiv, Inc. stock logo
NOTV
Inotiv
N/A
0.27
0.21
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/A
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
N/A
0.66
0.66

Institutional Ownership

CompanyInstitutional Ownership
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
29.64%
Inotiv, Inc. stock logo
NOTV
Inotiv
18.17%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.02%
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
11.61%

Insider Ownership

CompanyInsider Ownership
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
0.36%
Inotiv, Inc. stock logo
NOTV
Inotiv
7.80%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
2.60%
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
5.27%
CompanyEmployeesShares OutstandingFree FloatOptionable
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
845.11 million1.05 millionN/A
Inotiv, Inc. stock logo
NOTV
Inotiv
2,04634.89 million32.17 millionOptionable
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
800551.28 million536.95 millionNo Data
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
203.41 million3.23 millionNo Data

Recent News About These Companies

TRACON Pharma (OTC:TCON) Stock, Short Interest Report
October 5, 2024  |  benzinga.comhttps://www.benzinga.com/quote/TCON/short-interest
TRACON Pharmaceuticals Announces it Will Wind Down Operations
July 30, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/07/30/2921433/10391/en/tracon-pharmaceuticals-announces-it-will-wind-down-operations.html
TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
June 11, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/06/11/2896712/10391/en/tracon-announces-publication-in-clinical-cancer-research-of-phase-2-clinical-data-for-trc102-a-dna-damage-repair-inhibitor-in-recurrent-glioblastoma-patients.html
TRACON Pharmaceuticals Inc (NASDAQ:TCON) Stock Price Settled at $1.49: What’s Resulting?
May 27, 2024  |  bovnews.comB
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q1 2024 Earnings Call Transcript
May 15, 2024  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/tracon-pharmaceuticals-inc-nasdaqtcon-q1-2024-earnings-call-transcript/ar-BB1mqOyK
Q1 2024 TRACON Pharmaceuticals Inc Earnings Call
May 15, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/q1-2024-tracon-pharmaceuticals-inc-105310624.html?.tsrc=rss
TRACON Pharmaceuticals Inc (TCON) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
May 15, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/tracon-pharmaceuticals-inc-tcon-q1-071015646.html?.tsrc=rss
TCON Stock Earnings: TRACON Pharma Misses EPS for Q1 2024
May 14, 2024  |  investorplace.comhttps://investorplace.com/earning-results/2024/05/tcon-stock-earnings-tracon-pharma-for-q1-of-2024/?utm_source=Tradesmith&utm_medium=referral
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 14, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/tracon-pharmaceuticals-reports-first-quarter-200100042.html
Tracon: Q1 Earnings Snapshot
May 14, 2024  |  timesunion.comT
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 14, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/05/14/2881830/10391/en/tracon-pharmaceuticals-reports-first-quarter-2024-financial-results-and-provides-corporate-update.html
TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
May 7, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/05/07/2877173/10391/en/tracon-to-report-first-quarter-2024-financial-results-and-provide-corporate-update-on-may-14-2024.html
TRACON Pharmaceuticals Inc
April 26, 2024  |  money.usnews.comhttps://money.usnews.com/investing/stocks/tcon-tracon-pharmaceuticals-inc/vitals
Buy Rating Reaffirmed for TRACON Pharmaceuticals Post-Reverse Split and Envafolimab Valuation Update
April 10, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/buy-rating-reaffirmed-for-tracon-pharmaceuticals-post-reverse-split-and-envafolimab-valuation-update-1033238463
TRACON announces 1-for-20 reverse stock split
April 10, 2024  |  uk.investing.comhttps://uk.investing.com/news/stock-market-news/tracon-announces-1for20-reverse-stock-split-93CH-3422554
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024
April 10, 2024  |  investorplace.comhttps://investorplace.com/2024/04/wall-street-favorites-3-penny-stocks-with-strong-buy-ratings-for-april-2024/
Shares of Tracon Pharmaceuticals Tumble 22% on Reverse Split
April 8, 2024  |  marketwatch.comhttps://www.marketwatch.com/story/shares-of-tracon-pharmaceuticals-tumble-22-on-reverse-split-997bdc19
TRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Announces Reverse Stock Split
April 8, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-04/61890558-tracon-pharmaceuticals-inc-tracon-pharmaceuticals-announces-reverse-stock-split-399.htm
TRACON Pharmaceuticals Announces Reverse Stock Split
April 8, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/04/08/2859242/10391/en/tracon-pharmaceuticals-announces-reverse-stock-split.html
Buy Rating Affirmed for TRACON Pharmaceuticals Amid Promising Envafolimab Trial Outlook
April 4, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/buy-rating-affirmed-for-tracon-pharmaceuticals-amid-promising-envafolimab-trial-outlook-1033220294

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERo Therapeutics stock logo

CERo Therapeutics NASDAQ:CERO

$0.01 0.00 (0.00%)
As of 12:26 PM Eastern

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

Inotiv stock logo

Inotiv NASDAQ:NOTV

$0.01 0.00 (-26.00%)
As of 07/17/2026

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.

Sorrento Therapeutics stock logo

Sorrento Therapeutics NASDAQ:SRNE

$0.0004 0.00 (-20.00%)
As of 02:13 PM Eastern

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

TRACON Pharmaceuticals stock logo

TRACON Pharmaceuticals NASDAQ:TCON

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas